Pedro Gabriel Melo de Barros e Silva

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Alexandre Biasi Cavalcanti, Fernando G Zampieri, Régis Goulart Rosa et al. · New England Journal of Medicine · 2020 · 1.1K citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial

Renato D. Lópes, Pedro Gabriel Melo de Barros e Silva, Remo H.M. Furtado et al. · The Lancet · 2021 · 496 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +12

Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19

Renato D. Lópes, Ariane Vieira Scarlatelli Macedo, Pedro Gabriel Melo de Barros e Silva et al. · JAMA · 2021 · 381 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +6

Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve

Hélio Penna Guimarães, Renato D. Lópes, Pedro Gabriel Melo de Barros e Silva et al. · New England Journal of Medicine · 2020 · 281 citations

Medicine, Cardiology, Pharmacotherapy +12

Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia

Jeffrey L. Carson, Maria M. Brooks, Paul C. Hébert et al. · New England Journal of Medicine · 2023 · 247 citations · Full text

Medicine, Cardiology, Hematology +14